-
Uncategorized2 weeks ago
Lilly is pharma’s top dog, placing first in innovation and invention: IDEA
Lilly is pharma’s top dog, placing first in innovation and invention: IDEA
-
Uncategorized2 weeks agoSTAT+: Eli Lilly to buy three small vaccine developers
Eli Lilly said Tuesday it would buy three early- and mid-stage vaccine developers, a boost for the field. The deals — which together could cost up...
-
Uncategorized2 weeks ago
Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study
A single 1-mg/kg dose of Eli Lilly’s base editor can lower LDL cholesterol levels by 62% in patients with a heritable form of hypercholesterolemia. The pharma...
-
Uncategorized2 weeks ago
Process intensification: Separating fact from fiction
Uncover four key misconceptions that could be holding your intensification strategies back — and how to set your initiatives up for success. Read More
-
Uncategorized2 weeks agoOpinion: 8 former CDC directors: Reform PEPFAR, don’t dismantle it
On Sunday, the World Health Organization (WHO) declared an Ebola outbreak in the Democratic Republic of the Congo and Uganda to be a public health emergency....
-
Uncategorized2 weeks ago
All eyes on Revolution, bispecific antibodies and more at ASCO26
Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual conference with data from their potential Keytruda...
-
Uncategorized2 weeks ago
4 troubled targets that have thwarted biopharma
4 troubled targets that have thwarted biopharma
-
Uncategorized2 weeks ago
REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies
Analysts homed in on Duchenne muscular dystrophy and myotonic dystrophy type 1 assets during first quarter earnings as major players like REGENXBIO and Novartis as well...
-
Uncategorized3 weeks ago
Author Correction: DNA-guided CRISPR–Cas12a effectors for programmable RNA recognition and cleavage
Nature Biotechnology, Published online: 26 May 2026; doi:10.1038/s41587-026-03180-7 Author Correction: DNA-guided CRISPR–Cas12a effectors for programmable RNA recognition and cleavage
-
Uncategorized3 weeks agoSTAT+: Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study
Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial, an early but...
Amgen shores up Tavneos’ FDA defense with Duke data analysis
